Latest Conference Articles

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie Nahas-Geiger, MD

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie Nahas-Geiger, MD

April 19th 2021, 2:00pm

American Academy of Neurology Annual Meeting

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

April 18th 2021, 8:00pm

American Academy of Neurology Annual Meeting

The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.

Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

April 18th 2021, 6:00pm

American Academy of Neurology Annual Meeting

Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.

Switch to Siponimod Safe, Tolerable With No Washout, Study Finds

Switch to Siponimod Safe, Tolerable With No Washout, Study Finds

April 18th 2021, 2:00pm

American Academy of Neurology Annual Meeting

Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.

Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease

Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease

April 18th 2021, 11:00am

American Academy of Neurology Annual Meeting

No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.

Simple Interventions Improve Compliance With Patient-Specific Stroke Discharge Instructions

Simple Interventions Improve Compliance With Patient-Specific Stroke Discharge Instructions

April 17th 2021, 7:00pm

American Academy of Neurology Annual Meeting

Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions.

Disparities in Stroke Rehabilitation: Sana Somani, MD, MBBS

Disparities in Stroke Rehabilitation: Sana Somani, MD, MBBS

April 17th 2021, 5:00pm

American Academy of Neurology Annual Meeting

The vascular neurology fellow at the University of Maryland Medical Center discussed findings that African American women had the lowest functional performance in stroke rehabilitation.

Rimegepant Safe in Patients With Prior Triptan Failure

Rimegepant Safe in Patients With Prior Triptan Failure

April 17th 2021, 2:00pm

American Academy of Neurology Annual Meeting

Serious adverse events occurred in 3.7% and 2.4% of subjects in the subgroups of patients with 1 and 2 or more triptan failures, respectively.

Role of Social Determinants in Epilepsy Treatment Delays: Joseph Sirven, MD

Role of Social Determinants in Epilepsy Treatment Delays: Joseph Sirven, MD

April 17th 2021, 2:00pm

American Academy of Neurology Annual Meeting

The professor of neurology at Mayo Clinic discussed the reasoning for the research he presented at AAN 2021 on social determinants and their impact on epilepsy treatment times.

Negative Impacts on Cognition Not Observed With Pimavanserin for Dementia-Related Psychosis

Negative Impacts on Cognition Not Observed With Pimavanserin for Dementia-Related Psychosis

April 16th 2021, 9:00pm

American Academy of Neurology Annual Meeting

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.